Metamizol Stada (Metamizole Sodium Monohydrate)

Metamizole sodium is employed for the management of pain and fever through its analgesic and antipyretic actions.

• Acute pain: provides rapid relief of moderate to severe pain such as postoperative or injury‑related discomfort.
• Fever: reduces elevated body temperature in acute febrile states.
• Colicky abdominal pain: alleviates spasm‑related gastrointestinal pain.

• Metamizole sodium inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, and also modulates central pain pathways by acting on spinal and supraspinal receptors. This dual action diminishes peripheral inflammation and alters pain signal transmission, producing analgesic and antipyretic effects without significant opioid receptor involvement.

Metamizole sodium may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional emesis after dosing.
• Dizziness: transient light‑headedness.
• Headache: mild cranial discomfort.
• Rash: skin erythema or mild itching.
• Hypotension: occasional drop in blood pressure.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening.
• Anaphylaxis: rapid, severe allergic reaction requiring emergency care.
• Blood dyscrasias: including thrombocytopenia and aplastic anemia.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic enzyme elevation: possible liver function disturbance.
• Hemorrhagic events: increased bleeding tendency.

When prescribing Metamizol Stada, clinicians should consider several safety measures.

• Assess renal and hepatic function: evaluate before initiating therapy.
• Monitor blood counts: especially for agranulocytosis during prolonged use.
• Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
• Use with caution in elderly: increased risk of adverse events.
• Avoid concomitant use with other pyrazolones or myelosuppressive drugs.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Metamizol Stada can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid)

• Concurrent use with other myelosuppressive agents: may increase risk of agranulocytosis.
• Combination with anticoagulants: may enhance bleeding risk.
• Co‑administration with strong CYP inhibitors (e.g., fluconazole): may raise plasma levels.
• Use with other NSAIDs: increased gastrointestinal toxicity.
• Interaction with allopurinol: may potentiate hypersensitivity.

Moderate Interactions (Monitor Closely)

• Concurrent opioid analgesics: may mask pain signs.
• Combination with antihypertensives: may potentiate hypotensive effect.
• Use with diuretics: monitor electrolyte balance.
• Co‑administration with methotrexate: monitor for bone marrow suppression.
• Interaction with sulfonamides: possible additive blood dyscrasia risk.